A vaccine Pfizer is developing protected older adults against the respiratory syncytial virus, or RSV, which is a common cause of hospitalization and death in the U.S., the company said Thursday.
The experimental vaccine, known as RSVpreF, is considered a key product in Pfizer’s pipeline of experimental drugs. Right now drug companies are close to launching several different products against RSV, focused on protecting both older adults and infants.
Pfizer said that the vaccine reduced the risk of lower-respiratory tract illness with two or more symptoms that was caused by the virus by 66.7%. An analysis of more severe cases, defined as those with three or more symptoms, showed that those cases were reduced 85.7%. There were 37,000 participants in the placebo-controlled study, age 60 and up.